Recombinant Oxgr1 is utilized to study its role in:
Ligand Binding: αKG and itaconate activate Oxgr1 at millimolar concentrations, triggering intracellular Ca²⁺ signaling and Gq/11-mediated pathways .
Cysteinyl Leukotriene Interactions: LTE4 binding to Oxgr1 regulates airway inflammation and brush cell proliferation in respiratory tissues .
Metabolic Regulation: Oxgr1 modulates glucose and lipid metabolism in skeletal muscle, influencing capillary density and fiber-type composition .
Oxgr1 ablation in mice exacerbates pressure overload-induced hypertrophy, while its overexpression reduces cardiomyocyte enlargement. Mechanistically, Oxgr1 interacts with CSN5 (COP9 subunit 5) to suppress STAT3 signaling, a pro-hypertrophic pathway .
In diabetic models, Oxgr1 mediates αKG-induced upregulation of the (pro)renin receptor (PRR) and GLUT1 in collecting duct cells, contributing to sodium retention and angiotensin II formation .
Oxgr1 knockout mice exhibit reduced muscle mass, capillary density, and oxidative fiber content. Recombinant Oxgr1 may be used to study its role in vascular smooth muscle relaxation and metabolic adaptation .
Recombinant Oxgr1 is validated for:
ELISA/Western Blotting: Antibodies like A12225 (Boster Bio) detect Oxgr1 in rat tissues and recombinant proteins .
Functional Assays: αKG-induced Ca²⁺ influx and ERK phosphorylation are quantified in Xenopus oocytes expressing Oxgr1 .
Target Validation: Recombinant Oxgr1 aids in identifying antagonists (e.g., ML) to inhibit pathways linked to asthma, diabetes, or cardiac disease .
Drug Development: Structural studies using recombinant Oxgr1 inform the design of small-molecule modulators targeting its hydrophobic pocket (e.g., ARG110, HIS114 residues) .